Discuss This Drug

linaclotide

CHEBI:CHEBI_68551

Definition

A fourteen-membered heterodetic cyclic peptide consisting of Cys, Cys, Glu, Tyr, Cys, Cys, Asn, Pro, Ala, Cys, Thr, Gly, Cys and Tyr residues joined in sequence and cyclised by three disulfide bonds: between Cys(1) and Cys(6), between Cys(2) and Cys(10), and between Cys(5) and Cys(13). Used for treatment of irritable bowel syndrome accompanied by constipation.

Chemical Information

Molecular Formula
C59H79N15O21S6
Molecular Mass
1526.73600
Charge
0
SMILES
[H][C@]1(CSSC[C@]2([H])NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]3CSSC[C@H](NC(=O)[C@H](C)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CSSC[C@H](N)C(=O)N3)NC2=O)C(=O)N[C@@]([H])([C@@H](C)O)C(=O)NCC(=O)N1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O
InChI
InChI=1S/C59H79N15O21S6/c1-26-47(82)69-41-25-101-99-22-38-52(87)65-33(13-14-45(80)81)49(84)66-34(16-28-5-9-30(76)10-6-28)50(85)71-40(54(89)72-39(23-97-96-20-32(60)48(83)70-38)53(88)67-35(18-43(61)78)58(93)74-15-3-4-42(74)56(91)63-26)24-100-98-21-37(64-44(79)19-62-57(92)46(27(2)75)73-55(41)90)51(86)68-36(59(94)95)17-29-7-11-31(77)12-8-29/h5-12,26-27,32-42,46,75-77H,3-4,13-25,60H2,1-2H3,(H2,61,78)(H,62,92)(H,63,91)(H,64,79)(H,65,87)(H,66,84)(H,67,88)(H,68,86)(H,69,82)(H,70,83)(H,71,85)(H,72,89)(H,73,90)(H,80,81)(H,94,95)/t26-,27+,32-,33-,34-,35-,36-,37-,38-,39-,40-,41-,42-,46-/m0/s1
InChIKey
KXGCNMMJRFDFNR-WDRJZQOASA-N

Alternative Names

  • Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (disulfide bridge: 1-6; 2-10; 5-13)
  • L-cysteinyl-L-cysteinyl-L-alpha-glutamyl-L-tyrosyl-L-cysteinyl-L-cysteinyl-L-asparaginyl-L-prolyl-L-alanyl-L-cysteinyl-L-threonylglycyl-L-cysteinyl-L-tyrosine cyclic (1->6),(2->10),(5->13)-tris(disulfide)
  • Linzess

Drug Classification

Important Medical Information

⚕️ This information is sourced from ChEBI (Chemical Entities of Biological Interest) database and is intended for educational purposes only.

  • Always consult with a healthcare professional before starting, stopping, or modifying any medication.
  • Side effects may vary and this list may not be comprehensive.
  • Drug interactions may occur with other medications.

Additional Identifiers

core#notation
CHEBI:68551
DRON_00010000
1307404
oboInOwl#hasDbXref
Wikipedia:Linaclotide

Additional References

Wikipedia:Linaclotide

🔍 Click on any linked disease name to learn more about the conditions this medication is used to treat, or explore related drug classifications for more information about similar medications.

Additional Attributes

core#notation
CHEBI:68551
rxcui
1869699
manufacturer_name
Allergan, Inc.
active_ingredient_strength
290 ug/1
package_marketing_start_date
31-MAR-16
active_ingredient_name
LINACLOTIDE
unii
N0TXR0XR5X
spl_set_id
09beda19-56d6-4a56-afdc-9a77b70b2ef3
nui
N0000185499
upc
0304561201303
pharm_class_epc
Guanylate Cyclase-C Agonist [EPC]
pharm_class
Guanylate Cyclase Activators [MoA]
pharm_class_moa
Guanylate Cyclase Activators [MoA]
package_description
1 BAG in 1 DRUM (0456-1204-00) / 51000 CAPSULE, GELATIN COATED in 1 BAG
22-rdf-syntax-ns#type
http://www.w3.org/2002/07/owl#Class
oboInOwl#hasOBONamespace
chebi_ontology
DRON_00010000
1307404
oboInOwl#hasDbXref
Wikipedia:Linaclotide
oboInOwl#id
CHEBI:68551
generic_name
Linaclotide
brand_name
Linzess
brand_name_base
Linzess
product_type
BULK INGREDIENT
marketing_category
BULK INGREDIENT
labeler_name
MSN Life Sciences Private Limited
listing_expiration_date
20241231
route
ORAL
dosage_form
CAPSULE, GELATIN COATED
marketing_start_date
20120908
product_ndc
59651-011
application_number
NDA202811
spl_id
a82b5adc-8e7f-449e-a3ac-dabc3e728577
package_ndc
59651-011-37
oboInOwl#inSubset
http://purl.obolibrary.org/obo/chebi#3_STAR
RO_0000087
http://purl.obolibrary.org/obo/CHEBI_68553
has_treatment
http://purl.obolibrary.org/obo/DOID_9778
rdf-schema#domain
https://w3id.org/def/predibionto#has_side_effect32342
owl#annotatedSource
t273302
owl#someValuesFrom
t1123777